ArticleFrontiers in immunology2026
Microbiota metabolite butyrate alleviates intestinal inflammation associated with enhanced autophagy-related signaling in DSS-induced colitis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of inflammatory bowel disease (IBD) has been demonstrated to be increased over recent decades. Butyrate derived from the gut microbiota is known to be beneficial in alleviating inflammation, yet the underlying mechanisms remain undefined. Methods: Human and mice fecal samples were analyzed using gas chromatography-mass spectrometry and 16S rRNA gene sequencing. Male wild-type C57BL/6J mice aged 6-8 weeks old were administered dextran sodium sulfate (DSS) to induce experimental colitis models. Mice were treated with sodium butyrate (SB) through oral gavage. 3-methyladenine (3MA) was administered intraperitoneally to suppress autophagy in mice. Results: Our results showed that the butyric acid level in the feces of IBD patients was significantly lower than those in healthy controls (HCs) (134.5 vs. 605.9, Conclusion: Our findings provide multi-line evidence that SB coordinates gut microbiota and is associated with enhanced autophagy-related signaling to alleviate inflammation in DSS-induced colitis, integrating human fecal metabolomic and microbiome analyses with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.